Anonymous
Guest
Anonymous
Guest
UPDATE 2-US FDA staff-Novartis gout drug data 'complicated'
Fri Jun 17, 2011 10:41am EDT
* Drug reduces pain but infection risks seen
* Novartis shares flat (Adds FDA staff, Novartis, analyst comments)
By Lisa Richwine
WASHINGTON, June 17 (Reuters) - A Novartis AG (NOVN.VX) (NVS.N) medicine reduced pain from gout but also appeared to raise the chances of serious infections and other problems, U.S. drug reviewers said.
Food and Drug Administration staff, in documents released on Friday, said determining whether the benefits of Ilaris outweighed risks was "complicated" in part because the product has extended effects in the body that are not typical of an acute treatment. The impact of just a single injection may be "protracted," FDA reviewer Sarah Yim wrote in a memo to an advisory panel that meets Tuesday.
The panel of outside experts will decide whether to recommend approval of Ilaris, another crappy novartis overpriced drug, for gout and juvenile rheumatoid arthritis,
which is now sold for treating a rare inflammatory disorder.
(edited for proper content)
and you wonder why execs are dumping the stock & posting love threads ???
Can you say Enron the sequel ?
Fri Jun 17, 2011 10:41am EDT
* Drug reduces pain but infection risks seen
* Novartis shares flat (Adds FDA staff, Novartis, analyst comments)
By Lisa Richwine
WASHINGTON, June 17 (Reuters) - A Novartis AG (NOVN.VX) (NVS.N) medicine reduced pain from gout but also appeared to raise the chances of serious infections and other problems, U.S. drug reviewers said.
Food and Drug Administration staff, in documents released on Friday, said determining whether the benefits of Ilaris outweighed risks was "complicated" in part because the product has extended effects in the body that are not typical of an acute treatment. The impact of just a single injection may be "protracted," FDA reviewer Sarah Yim wrote in a memo to an advisory panel that meets Tuesday.
The panel of outside experts will decide whether to recommend approval of Ilaris, another crappy novartis overpriced drug, for gout and juvenile rheumatoid arthritis,
which is now sold for treating a rare inflammatory disorder.
(edited for proper content)
and you wonder why execs are dumping the stock & posting love threads ???
Can you say Enron the sequel ?